Business
Esperion Announces Publication of Phase 3 Data for Bempedoic Acid in the Journal of Clinical Lipidology
Analysis of pooled Phase 3 data demonstrated 26.5% reduction vs. placebo in LDL-C from bempedoic acid monotherapy and 39.2% reduction vs. placebo in LDL-C
About this update from Esperion Therapeutics, Inc.
[{"type":"text","content":"Analysis of pooled Phase 3 data demonstrated 26.5% reduction vs. placebo in LDL-C from bempedoic acid monotherapy and 39.2% reduction vs. placebo in LDL-C from bempedoic acid and ezetimibe fixed-dose combination in patients not taking statins\nANN ARBOR, Mich., April 13, 2022 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced the publication of data from a pooled analysis of patients enrolled in four Phase 3 bempedoic acid studies in the Journal of Clinical Lipidology. The paper, “Efficacy and safety of bempedoic acid in patients not receiving statins in phase 3 clinical trials,” discussed a pooled analysis of data from patients enrolled in four Phase 3 bempedoic acid studies, 12 to 52 weeks in duration, who were not taking concomitant statins (n=394), and a Phase 3 bempedoic acid plus ezetimibe fixed-dose combination study (n=33). The objective of the studies was to assess the LDL-C lowering effect of bempedoic acid in patients not taking statins measured as percent change in LDL-C from baseline to week 12. “Although statins are the mainstay of lipid-lowering treatment, 1 out of 5 individuals with a clinical indication for statin therapy are unable to take a daily statin because of side effectsi and more than half (45–70%) of patients discontinue their statin therapy within 1–2 years after initiationii,” said JoAnne Foody, M.D., FACC, FAHA, chief medical officer of Esperion. “The results from this pooled analysis evaluating bempedoic acid monotherapy and a fixed-dose combination with ezetimibe in patients not taking statins suggest that bempedoic acid could be an effective and generally well-tolerated option for these patients, but further study is warranted. Esperion’s ongoing global CLEAR Outcomes trial, evaluating the effects of bempedoic acid on statin-intolerant patients, will expand the existing body of knowledge on lipid management for this underserved patient group and offer key insights into managing LDL-C without the use of statins.” The results of the analysis demonstrated that in patients with hypercholesterolemia who are unable to take statins, bempedoic acid monotherapy resulted in a 26.5% mean reduction in LDL-C (p","length":2358,"tagName":"div"}]